This European biotech company could rally nearly 45%, says Morgan Stanley

  • 📰 CNBC
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 72%

Malaysia News News

Malaysia Malaysia Latest News,Malaysia Malaysia Headlines

Morgan Stanley is bullish on pelabresib, currently awaiting results from its Phase 3 MANIFEST-2 trial.

Recent data for cancer treatment manufacturer MorphoSys AG suggests the German biotech's shares could see a significant rally, according to Morgan Stanley. The bank upgraded MorphoSys American depositary shares to overweight from underweight on Friday, and raised its price target to $9.20 from $3.70, implying 45% upside from Thursday's close. "Despite increasing competition, our updated analysis suggests peak global sales of $1.

"In addition, while some clinical risk remains, the data so far suggests that MANIFEST-2 has a good chance of success, which should drive significant upside in the shares," Quigley said. To be sure, the analyst noted that "binary outcome and profit taking" have led to weak MorphoSys shares in recent weeks, but the risk-reward profile is positively skewed at current prices, he added.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in MY
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Malaysia Malaysia Latest News, Malaysia Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

European stocks mixed; Chinese trade, European inflation data in focusEuropean stocks mixed; Chinese trade, European inflation data in focus
Source: Investingcom - 🏆 450. / 53 Read more »